Despite some recent setbacks to its sickle cell disease (SCD) pipeline, Pfizer is plowing ahead in improving education around ...

Before joining Priovant, the new Abcuro executive spent more than a decade at Genzyme before its acquisition by Sanofi, ...

A new era of hypertension treatment is on the horizon for U.S. | The drug is the first triple-combo pill for the initial ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

After delivering strong sales growth last year and with more expansion in mind, CDMO giant Wuxi Biologics is breaking ground ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

After two years of quietly shifting its medical affairs and commercial strategy units under one roof, Astellas is entering a ...

Rechon Life Sciences, a Sweden-based pharma contract manufacturer, was hit with a warning letter from the FDA following an ...

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

Orca Bio is preparing to make a splash in the cell therapy market. | Orca Bio is preparing to make a splash in the cell ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...